Suggestions
Kandaswamy (Swamy) Vijayan
Chief Executive Officer at Zafrens
Kandaswamy (Swamy) Vijayan is an accomplished executive and scientist with extensive experience in biotechnology and entrepreneurship. He is currently the Chief Executive Officer of Zafrens, a position he has held since January 2022.1 Zafrens is a company that has developed a versatile platform to probe complex biological questions.1
Career Highlights
Previous Leadership Roles::
- CEO of Plexium (November 2017 - April 2021): Developed a novel therapeutic approach for protein degradation.1
- CEO of Omniome Inc. (November 2013 - June 2017): Worked on developing innovative sequencing technologies.1
Scientific Contributions::
- At Illumina (March 2011 - November 2013): Led the nanopore sequencing program and contributed to the development of next-generation sequencing technology.1
- As an independent scientist/entrepreneur (June 2009 - March 2011): Focused on high-speed optical and electrical detection of single molecule transport and novel sequencing platforms.1
Educational Background
Vijayan has a strong academic foundation:
- Ph.D. in Physics from the University of Pennsylvania (2002-2007)1
- B.Sc. in Physics from the Indian Institute of Technology, Kharagpur (1997-2001)1
- Executive training from the University of California, San Diego (2012-2013)1
Expertise
Swamy Vijayan's expertise spans multiple disciplines, including:
- Nanobiotechnology
- DNA sequencing and mapping
- Single molecule imaging and detection
- Nanofluidics and surface chemistry
- Algorithm development and programming
His diverse skill set allows him to bridge the gap between biological, physical, computational, and engineering sciences.1
Highlights
Had a great time chatting with Elliot and Anastasia, and a big thanks to BlueYard Capital for suggesting the idea. At Zafrens, we're doing foundational work that encapsulates a lot of possibilities even in the few things we do. I had the opportunity to talk about our immunotherapy work in this discussion, and will look forward to sharing more nuances over time. https://lnkd.in/gnQpz5Wd
[For the broader context - the function of a cell is dictated by the levels and/or sequences of various molecules it contains. It's been hard to measure the molecules in a cell and simultaneously study what they make the cell do (or, equivalently, predict how the molecules reconfigure if the cells is disturbed by drugs, and its consequences on the cell). Most of our progress in biology has come from charting this ome-to-function map in small, tiny increments - by altering levels or sequence of one molecule at a time, for instance. But even a 10 base sequence of DNA can exist in ~1 million forms, so studying cells at low throughput only tells us so much. Zafrens unleashes our ability to map lots, and lots of molecular changes to each of their individual functional effects. The implications of this touches all of biology, because once you have dense maps of 'cause-and-effect', we can start predicting (and engineering) desired cell states and cell behavior more accurately. Could this help predict if a molecule will work for a patient? We think so. Rather than empirically observing physiological responses and cell-functional responses, we feel understanding how the collection of molecules inside a cell respond could give us more predictive information. That is what we are excited to prove to ourselves, but along the way we are eager to unlock lots of other transformative opportunities with our high-throughput, high-resolution peek into biology].
Hello everyone, I am delighted to share our financing update https://t.ly/iYcy7. We are just getting started in our mission to change how drug discovery (and all bio/chem/AI) experiments are done, so more updates to come; today, I'd like to take the opportunity to acknowledge the immense amount of work that our team has put in to solve some of the foundational challenges in biology. At Zafrens we are able to simultaneously image and sequence cells such that the molecular underpinnings of complex cell behavior becomes apparent - at massive scale.
The implications of this ability are enormous (e.g., for large libraries of CRISPR probes one can map what each of the edits do to a cell functionally; for instance, could one edit enhance T cell killing? could one make a stem cell more proliferative, etc. Because this can be done for ALL the edits, it becomes the highest throughput machine learning tool in biology. The approach is agnostic to the perturbations - we can use other cells incubated with a cell of interest to monitor cell-cell interactions, and also use large chemical libraries to map drug-cell interactions with multiomics and functional response. This is a reimagination of experiments we all do in the lab from the ground-up; we can do this on a bench top at a scale that only very-big pharma has been able to afford so far).
We feel an immense responsibility to shepherd these innovations to have the most social impact, so we are grateful to Prime Movers Lab, BlueYard Capital, and our other investors who have believed in us and supported our mission so far. Justin Briggs, Juan Bautista Pinilla and Jason D. Whitmire have been the best partners an entrepreneur could hope for, especially in this turbulent environment. Thank you!
We have ambition in spades, so we will raise more money and build more partnerships, when we do so we will need more friends who can grow the company with us. We are always interested in interdisciplinary skills and an ability to collaborate with people from diverse backgrounds. We are also always interested in speaking with experienced leaders in different therapeutic modalities who are open to new ways of advancing medicines. We would love to chat with BD folks who are curious about our approach, as well.
Looking forward to an exciting 2024!
